Publikationen von Tanya Dogra
Alle Typen
Zeitschriftenartikel (5)
1.
Zeitschriftenartikel
108, 97 (2024)
Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus. Applied Microbiology and Biotechnology 2.
Zeitschriftenartikel
13, 20936 (2023)
Generation of “OP7 chimera” defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice. Scientific Reports 3.
Zeitschriftenartikel
107, S. 5947 - 5961 (2023)
Production of retroviral vectors in continuous high cell density culture. Applied Microbiology and Biotechnology 4.
Zeitschriftenartikel
11, 1076524 (2023)
Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactors. Frontiers in Bioengineering and Biotechnology 5.
Zeitschriftenartikel
95 (24), e01174-21 (2021)
Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapy. Journal of Virology Meeting Abstract (1)
6.
Meeting Abstract
53 (2) Special Issue: SI Aufl., P339. Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI), Strasbourg (France), 26. September 2023 - 29. September 2023. Wiley-VCH, Weinheim (2023)
Characterization of the local innate immune response after mucosal application of IAV Defective Interfering Particles. In European Journal of Immunology, Vortrag (8)
7.
Vortrag
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17th Vaccine Congress, Glasgow (Scotland) (2023)
8.
Vortrag
Reverse genetics for Influenza a virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. Vir-AI-DIP Workshop , Hamburg (Germany) (2023)
9.
Vortrag
Influenza A virus defective interfering particles as antiviral agents. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
10.
Vortrag
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
11.
Vortrag
Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
12.
Vortrag
Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)
13.
Vortrag
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
14.
Vortrag
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
Poster (10)
15.
Poster
Genetically engineered defective interfering particles for antiviral treatment and vaccination. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
16.
Poster
Defective Interfering Particles of Influenza A Virus As Broad-Spectrum Antivirals. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
17.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
18.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8th European Congress of Virology, Gdańsk (Poland) (2023)
19.
Poster
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
20.
Poster
A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)